Clínic Barcelona

A triple therapy increases the sustained virological response in patients co-infected with HIV and hepatitis C virus

About a third of people infected with HIV in the USA and Europe are also infected with hepatitis C virus (HCV). A work published in The Lancet Infectious Diseases suggests a novel combination of drugs, already used successfully in HCV patients, which achieves a better sustained virological response in co-infected patients too. Dr. Josep Mallolas, from the AIDS and Infectious Diseases team at IDIBAPS - Hospital Clínic of Barcelona, is the third author of this work coordinated from the Johns Hopkins University School of Medicine (Baltimore, USA) and funded by Merck.